Despite the complex regulation and multiple interactions of SFN with different biomolecules, the reported anticancer mechanism is of potential interest to osteosarcoma therapy and deserves further investigation for this and other p53-null cancer cells that are chemoresistant. This evidence concerns the gene SFN and osteosarcoma.